342 related articles for article (PubMed ID: 31466944)
1. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.
Rasool RU; Natesan R; Deng Q; Aras S; Lal P; Sander Effron S; Mitchell-Velasquez E; Posimo JM; Carskadon S; Baca SC; Pomerantz MM; Siddiqui J; Schwartz LE; Lee DJ; Palanisamy N; Narla G; Den RB; Freedman ML; Brady DC; Asangani IA
Cancer Discov; 2019 Nov; 9(11):1538-1555. PubMed ID: 31466944
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1.
Russo JW; Nouri M; Balk SP
Cancer Discov; 2019 Nov; 9(11):1490-1492. PubMed ID: 31676563
[TBL] [Abstract][Full Text] [Related]
3. MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand.
Liu G; Sprenger C; Wu PJ; Sun S; Uo T; Haugk K; Epilepsia KS; Plymate S
Oncotarget; 2015 Jan; 6(1):288-304. PubMed ID: 25481872
[TBL] [Abstract][Full Text] [Related]
4. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer.
Dahiya NR; Chandrasekaran B; Kolluru V; Ankem M; Damodaran C; Vadhanam MV
Mol Carcinog; 2018 Oct; 57(10):1332-1341. PubMed ID: 30069922
[TBL] [Abstract][Full Text] [Related]
5. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
6. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
[TBL] [Abstract][Full Text] [Related]
7. Castration-resistant prostate cancer cells are dependent on the high activity of CDK7.
Pallasaho S; Gondane A; Kuivalainen A; Girmay S; Moestue S; Loda M; Itkonen HM
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5255-5263. PubMed ID: 36401094
[TBL] [Abstract][Full Text] [Related]
8. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
9. The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Constantin TA; Varela-Carver A; Greenland KK; de Almeida GS; Olden E; Penfold L; Ang S; Ormrod A; Leach DA; Lai CF; Ainscow EK; Bahl AK; Carling D; Fuchter MJ; Ali S; Bevan CL
Br J Cancer; 2023 Jun; 128(12):2326-2337. PubMed ID: 37076563
[TBL] [Abstract][Full Text] [Related]
10. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
12. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth.
Chen Z; Zhang C; Wu D; Chen H; Rorick A; Zhang X; Wang Q
EMBO J; 2011 May; 30(12):2405-19. PubMed ID: 21556051
[TBL] [Abstract][Full Text] [Related]
13. The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program.
Parolia A; Venalainen E; Xue H; Mather R; Lin D; Wu R; Pucci P; Rogalski J; Evans JR; Feng F; Collins CC; Wang Y; Crea F
Mol Oncol; 2019 May; 13(5):1121-1136. PubMed ID: 30776192
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.
Joshi JB; Patel D; Morton DJ; Sharma P; Zou J; Hewa Bostanthirige D; Gorantla Y; Nagappan P; Komaragiri SK; Sivils JC; Xie H; Palaniappan R; Wang G; Cox MB; Chaudhary J
Mol Oncol; 2017 Apr; 11(4):337-357. PubMed ID: 28252832
[TBL] [Abstract][Full Text] [Related]
16. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
17. Mediator kinase inhibition reverses castration resistance of advanced prostate cancer.
Li J; Hilimire TA; Liu Y; Wang L; Liang J; Gyorffy B; Sikirzhytski V; Ji H; Zhang L; Cheng C; Ding X; Kerr KR; Dowling CE; Chumanevich AA; Mack ZT; Schools GP; Lim CU; Ellis L; Zi X; Porter DC; Broude EV; McInnes C; Wilding G; Lilly MB; Roninson IB; Chen M
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38546787
[TBL] [Abstract][Full Text] [Related]
18. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
